Brief: Aeterna Zentaris Amends License Agreement With Novo Nordisk For Commercialization And Development Of Macimorelin

COSCIENS Biopharma

16/11/2020 13:30

Nov 16 (Reuters) - Aeterna Zentaris Inc  AEZS.TO :
    * AETERNA ZENTARIS AMENDS LICENSE AGREEMENT WITH NOVO
NORDISK FOR
COMMERCIALIZATION AND DEVELOPMENT OF MACIMORELIN
    * AETERNA ZENTARIS INC - CO TO RECEIVE UPFRONT PAYMENT OF
EUR 5
MILLION REPLACING A LATER STAGE REGULATORY APPROVAL MILESTONE OF
U.S.$5 MILLION
    * AETERNA ZENTARIS- NOVO NORDISK IS ADJUSTING PERCENT OF
STUDY P02
CLINICAL TRIAL COSTS THAT IT WILL REIMBURSE TO CO TO 100% OF
COSTS UP TO EUR 9 MILLION
    * AETERNA ZENTARIS- ANY EXTRA EXTERNAL JOINTLY APPROVED
STUDY P02
TRIAL COSTS INCURRED OVER EUR 9 MILLION TO BE SHARED EQUALLY
BETWEEN NOVO NORDISK,CO

Source text for Eikon:  ID:nGNX6dJfm2 
Further company coverage:  AEZS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))